Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Climb Bio, Inc. (CLYM : NSDQ)

• Company Description    Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass. Number of Employees: 28

• Price / Volume Information    Yesterday's Closing Price: $11.00 Daily Weekly Monthly 20 Day Moving Average: 945,215 shares Shares Outstanding: 57.26 (millions) Market Capitalization: $629.87 (millions) Beta: 0.02 52 Week High: $12.48 52 Week Low: $1.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 21.95% 15.99% 12 Week 49.05% 37.79% Year To Date 175.00% 150.76%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20 William Street Suite 145 - Wellesley Hills,MA 02481 USA ph: 866-857-2596 fax: - investorrelations@climbbio.com http://www.eliemtx.com

• General Corporate Information    Officers Aoife Brennan - President; Chief Executive Officer and Director Douglas E. Williams - Chairman Susan Altschuller - Chief Financial Officer Cindy J. Driscoll - Senior Vice President Kimberlee C. Drapkin - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28658R106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 57.26 Most Recent Split Date: (:1) Beta: 0.02 Market Capitalization: $629.87 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.89 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.25 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 35.48% vs. Previous Quarter: 23.08% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -31.45 12/31/25 - -33.41 09/30/25 - -26.43 ROA 03/31/26 - -30.39 12/31/25 - -32.21 09/30/25 - -25.61 Current Ratio 03/31/26 - 27.86 12/31/25 - 15.16 09/30/25 - 18.38 Quick Ratio 03/31/26 - 27.86 12/31/25 - 15.16 09/30/25 - 18.38 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 2.59 12/31/25 - 3.36 09/30/25 - 2.61 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©